Home/ Stocks/ STRO

Sutro Biopharma, Inc.

STRO XNAS

$40.24 +0.27 (+0.68%) ▲ 15-min delayed

Open

$39.91

High

$41.88

Low

$39.80

Volume

237.2K

Market Cap

$666.69M

About Sutro Biopharma, Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 137 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$102.48M	$-191,086,000	$-22.49
FY 2025	$102.48M	$-191,086,000	$-22.49
Q3 2025	$9.69M	$-56,857,000	$-0.67
Q2 2025	$63.74M	$-11,499,000	$-0.14

Earnings & Analyst Ratings

Next Earnings: Wed, Aug 5, 2026

Calendar →

Related Market News

No specific coverage for STRO yet. Check out our latest market news or earnings calendar.

Get STRO Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Sutro Biopharma, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.